Intermediary results of high dose PDC*lung01 combined with pembrolizumab show mild safety profile, immunological activity and promising tumor response in Non-Small Cell Lung Cancer patients
Combinatio...
We are delighted to announce that our abstract on the preliminary clinical results of the therapeutic cancer vaccine PDC*lung01 in patients (pts) with stage IV NSCLC was accepted for an oral...
PDC*line Pharma and partners receive €8.1M from Walloon region and Wallonia health cluster BioWin for personalized therapeutic vaccine project
- PDC*neo+ project aims to develop personalized therapeutic...
We are very pleased to announce the publication of a new scientific paper in the peer-reviewed journal "The Journal of Immunology". Title of the article is: "Development of a New Off-the-Shelf...
PDC*line Pharma completes enrolment of four cohorts of patients
in PDC-LUNG-101 phase I/II clinical trial.
Total of 67 patients dosed in four cohorts in PDC-LUNG-101 trial with PDC*lung01...
We are very pleased to announce the publication of a a new article with an interview of our CEO Eric Halioua published this week in the magazine PharmaBoardroom, the global platform for healthcare &...
Eric Halioua, President & CEO at PDC*line Pharma Shares Insights on the Results from ongoing PDC-LUNG-101 clinical trial
We are very pleased to announce that a new article, following an interview...
PDC*line Pharma will be presenting a poster in the “Therapeutic Vaccination” session of the 20th Cancer IMmunoTherapy (CIMT) annual meeting taking place from 3 to 5 May 2023, in Mainz (Germany). The...
We are delighted to announce that our CEO will be presenting at the 6th Europe Neoantigen Summit 2023 hosted by Hanson Wade in Amsterdam (Netherlands) from April 24-26th! He will be presenting PDC...
We are very pleased to inform you about the publication of a new scientific paper in the peer-reviewed journal "Genes and Cancer" as a "Research Perspective". Article is entitled: Leveraging a...
